18:55 , May 30, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Breast cancer Mouse studies suggest inhibiting MAP3K7 could help treat metastatic triple-negative breast cancer (TNBC). In a xenograft mouse model of metastatic TNBC, cross-linked multilamellar liposomal vesicles loaded with a tool compound MAP3K7 inhibitor or...
23:17 , Mar 27, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Lung cancer; melanoma; skin cancer Patient sample, cell culture and mouse studies suggest inhibiting ERK-5 in macrophages could help treat melanoma and lung cancer. In skin samples from patients with squamous cell carcinoma (SCC) of...
01:00 , Jan 3, 2018 |  BC Extra  |  Preclinical News

CYLD expression could slow progression of NASH

In a paper published in Nature Medicine, researchers at Wuhan University and Weill Cornell Medicine found that increasing expression of the deubiquitinating enzyme cylindromatosis turban tumor syndrome (CYLD) reversed progression of non-alcoholic steatohepatitis (NASH) in...
20:02 , Aug 31, 2017 |  BC Innovations  |  Targets & Mechanisms

Necroptosis strikes again

Adding to the list of necroptosis-related pathologies, a group from Arizona State University has shown the cell death pathway is activated in Alzheimer’s disease. The data, published last month in Nature Neuroscience, identify potential targets...
07:00 , Oct 8, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Tumor necrosis factor (TNF); MAP kinase kinase kinase 7 (MAP3K7; TAK1)

Neurology INDICATION: Neurology Mouse studies suggest anti-TNF antibodies or antioxidants could help treat the genetic neurological disease incontinentia pigmenti. In mice, brain endothelial cell-specific knockout of MAP3K7 recapitulated CNS features of the disease, including endothelial cell death,...
07:00 , Oct 24, 2013 |  BC Innovations  |  Distillery Techniques

Technology: Disease models

This week in techniques Approach Summary Licensing status Publication and contact information Disease models Chemokine CX3C motif receptor 1 (CX3CR1) promoter-dependent gene expression in microglia A microglia-specific expression...
08:00 , Nov 19, 2012 |  BioCentury  |  Emerging Company Profile

Confluence: KINecting discovery

Confluence Life Sciences Inc. is building a library of chemical probes that interact with cysteine-containing active sites of certain kinases, which could allow for quicker and more efficient discovery of inhibitors of difficult targets. A lead...
07:00 , Jun 21, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Lymphoma MAP kinase kinase kinase 7 (MAP3K7; TAK1) In vitro studies suggest TAK1 inhibitors could help treat...
08:00 , Mar 1, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Colon cancer MAP kinase kinase kinase 7 (MAP3K7; TAK1); K-Ras Cell culture and mouse studies suggest inhibiting...
07:00 , Jul 28, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Pancreatic cancer MAP kinase kinase kinase 7 (MAP3K7; TAK1) Mouse and cell culture studies suggest inhibiting TAK1...